All Stories

  1. Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice

    Article • Leukemia & Lymphoma, April 2019, Taylor & Francis

    Eli Muchtar, Amber Koehler